NO323174B1 - Immortalisert patterdyrcellelinje og fremgangsmate for immortalisering og dissimortalisering av celler - Google Patents
Immortalisert patterdyrcellelinje og fremgangsmate for immortalisering og dissimortalisering av celler Download PDFInfo
- Publication number
- NO323174B1 NO323174B1 NO19975557A NO975557A NO323174B1 NO 323174 B1 NO323174 B1 NO 323174B1 NO 19975557 A NO19975557 A NO 19975557A NO 975557 A NO975557 A NO 975557A NO 323174 B1 NO323174 B1 NO 323174B1
- Authority
- NO
- Norway
- Prior art keywords
- gene
- cells
- immortalization
- selection marker
- nucleic acid
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 61
- 210000004027 cell Anatomy 0.000 title claims description 281
- 210000004962 mammalian cell Anatomy 0.000 title claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 238
- 239000003550 marker Substances 0.000 claims description 137
- 108010091086 Recombinases Proteins 0.000 claims description 134
- 102000018120 Recombinases Human genes 0.000 claims description 127
- 150000007523 nucleic acids Chemical class 0.000 claims description 55
- 108020004707 nucleic acids Proteins 0.000 claims description 53
- 102000039446 nucleic acids Human genes 0.000 claims description 53
- 230000014509 gene expression Effects 0.000 claims description 29
- 239000013598 vector Substances 0.000 claims description 25
- 108010051219 Cre recombinase Proteins 0.000 claims description 22
- 230000001939 inductive effect Effects 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 230000001131 transforming effect Effects 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 2
- 210000000130 stem cell Anatomy 0.000 description 18
- 108700020796 Oncogene Proteins 0.000 description 15
- 230000001177 retroviral effect Effects 0.000 description 15
- 238000002054 transplantation Methods 0.000 description 15
- 101710101493 Viral myc transforming protein Proteins 0.000 description 13
- 238000010276 construction Methods 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 11
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 11
- 230000009466 transformation Effects 0.000 description 11
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 10
- 102000043276 Oncogene Human genes 0.000 description 10
- 239000005090 green fluorescent protein Substances 0.000 description 10
- 108700024542 myc Genes Proteins 0.000 description 10
- 238000001890 transfection Methods 0.000 description 10
- 241000282414 Homo sapiens Species 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 238000013519 translation Methods 0.000 description 9
- 230000012010 growth Effects 0.000 description 8
- 239000003102 growth factor Substances 0.000 description 8
- 230000006798 recombination Effects 0.000 description 8
- 238000005215 recombination Methods 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 210000002950 fibroblast Anatomy 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- 238000013461 design Methods 0.000 description 6
- 238000001415 gene therapy Methods 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 5
- 206010059866 Drug resistance Diseases 0.000 description 5
- 229930193140 Neomycin Natural products 0.000 description 5
- 229960001714 calcium phosphate Drugs 0.000 description 5
- 229910000389 calcium phosphate Inorganic materials 0.000 description 5
- 239000001506 calcium phosphate Substances 0.000 description 5
- 235000011010 calcium phosphates Nutrition 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 210000004153 islets of langerhan Anatomy 0.000 description 5
- 229960004927 neomycin Drugs 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 5
- 108700026220 vif Genes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 108010025020 Nerve Growth Factor Proteins 0.000 description 4
- 241000276498 Pollachius virens Species 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 239000013599 cloning vector Substances 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 4
- 229960002963 ganciclovir Drugs 0.000 description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 101150066555 lacZ gene Proteins 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 210000004498 neuroglial cell Anatomy 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 241001430294 unidentified retrovirus Species 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 3
- 108091092195 Intron Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 210000001178 neural stem cell Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 210000003014 totipotent stem cell Anatomy 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 108010046276 FLP recombinase Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 102000015336 Nerve Growth Factor Human genes 0.000 description 2
- 102000007072 Nerve Growth Factors Human genes 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 102000004230 Neurotrophin 3 Human genes 0.000 description 2
- 108090000742 Neurotrophin 3 Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 108010052160 Site-specific recombinase Proteins 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000011509 clonal analysis Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 230000009395 genetic defect Effects 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 238000001638 lipofection Methods 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 229940053128 nerve growth factor Drugs 0.000 description 2
- 229940032018 neurotrophin 3 Drugs 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 210000001428 peripheral nervous system Anatomy 0.000 description 2
- 108010085336 phosphoribosyl-AMP cyclohydrolase Proteins 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 229950010131 puromycin Drugs 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
- RJOXFJDOUQJOMQ-UHFFFAOYSA-N 6-sulfanylidene-3,7-dihydropurin-2-one Chemical compound S=C1NC(=O)NC2=C1NC=N2 RJOXFJDOUQJOMQ-UHFFFAOYSA-N 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 241000175212 Herpesvirales Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- ZQISRDCJNBUVMM-UHFFFAOYSA-N L-Histidinol Natural products OCC(N)CC1=CN=CN1 ZQISRDCJNBUVMM-UHFFFAOYSA-N 0.000 description 1
- ZQISRDCJNBUVMM-YFKPBYRVSA-N L-histidinol Chemical compound OC[C@@H](N)CC1=CNC=N1 ZQISRDCJNBUVMM-YFKPBYRVSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 208000002678 Mucopolysaccharidoses Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108700026495 N-Myc Proto-Oncogene Proteins 0.000 description 1
- 102000055056 N-Myc Proto-Oncogene Human genes 0.000 description 1
- 102000007530 Neurofibromin 1 Human genes 0.000 description 1
- 108010085793 Neurofibromin 1 Proteins 0.000 description 1
- 108010070047 Notch Receptors Proteins 0.000 description 1
- 102000005650 Notch Receptors Human genes 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 230000007022 RNA scission Effects 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010038997 Retroviral infections Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000010310 bacterial transformation Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 210000005064 dopaminergic neuron Anatomy 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 230000003721 exogen phase Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 231100000221 frame shift mutation induction Toxicity 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 101150106093 gpt gene Proteins 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 206010028093 mucopolysaccharidosis Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000000933 neural crest Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000007514 neuronal growth Effects 0.000 description 1
- 210000003924 normoblast Anatomy 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000001216 nucleic acid method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 238000011197 physicochemical method Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000014723 transformation of host cell by virus Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10041—Use of virus, viral particle or viral elements as a vector
- C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/481,127 US5629159A (en) | 1995-06-07 | 1995-06-07 | Immortalization and disimmortalization of cells |
PCT/US1996/009781 WO1996040877A1 (en) | 1995-06-07 | 1996-06-06 | Immortalization and disimmortalization of cells |
Publications (3)
Publication Number | Publication Date |
---|---|
NO975557D0 NO975557D0 (no) | 1997-12-02 |
NO975557L NO975557L (no) | 1998-02-05 |
NO323174B1 true NO323174B1 (no) | 2007-01-15 |
Family
ID=23910719
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19975557A NO323174B1 (no) | 1995-06-07 | 1997-12-02 | Immortalisert patterdyrcellelinje og fremgangsmate for immortalisering og dissimortalisering av celler |
Country Status (10)
Country | Link |
---|---|
US (1) | US5629159A (es) |
EP (1) | EP0832196B1 (es) |
JP (1) | JP3875267B2 (es) |
AT (1) | ATE255632T1 (es) |
AU (1) | AU700690B2 (es) |
CA (1) | CA2222425C (es) |
DE (1) | DE69630955T2 (es) |
ES (1) | ES2211959T3 (es) |
NO (1) | NO323174B1 (es) |
WO (1) | WO1996040877A1 (es) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6110743A (en) * | 1995-02-10 | 2000-08-29 | The Regents Of The University Of California | Development and use of human pancreatic cell lines |
US20030202967A1 (en) * | 1995-02-10 | 2003-10-30 | The Regents Of The University Of California | Development and use of human pancreatic cell lines |
FR2737731B1 (fr) * | 1995-08-07 | 1997-10-10 | Pasteur Institut | Sequence de retroelements naturels ou synthetiques ayant pour fonction de permettre l'insertion de sequences nucleotidiques dans une cellule eucaryote |
US6743620B1 (en) * | 1996-12-16 | 2004-06-01 | Eisai Co., Ltd. | Method for preparing retrovirus vector for gene therapy |
AU736267B2 (en) * | 1996-12-31 | 2001-07-26 | Omeros Corporation | Vectors and methods for the mutagenesis of mammalian genes |
DE19740571C1 (de) * | 1997-09-15 | 1999-03-18 | Gsf Forschungszentrum Umwelt | Verfahren zur Stimulation von T-Zellen mit gewünschter Antigenspezifität |
US6897066B1 (en) * | 1997-09-26 | 2005-05-24 | Athersys, Inc. | Compositions and methods for non-targeted activation of endogenous genes |
JP2001520877A (ja) * | 1997-10-28 | 2001-11-06 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 血管平滑筋細胞のインビトロ分化、それに関する方法および試薬 |
DE19816116C2 (de) * | 1998-04-09 | 2000-06-29 | Gsf Forschungszentrum Umwelt | Verfahren zur Immortalisation von Zellen mit Hilfe konditional transformierter Helferzellen |
AU6162199A (en) * | 1998-09-25 | 2000-04-17 | Harvard-Mit Division Of Health Science And Technology | Reversibly immortalized hepatocytes and methods of use |
NZ513598A (en) | 1999-01-21 | 2001-09-28 | Vitro Diagnostics Inc | Immortalized cell lines and methods of making the same |
US6890726B1 (en) | 1999-04-06 | 2005-05-10 | Oklahoma Medical Research Foundation | Method for selecting recombinase variants with altered specificity |
EP1103615A1 (en) * | 1999-11-25 | 2001-05-30 | Universite De Geneve | Vectors capable of immortalizing non-dividing cells and cells immortalized with said vectors |
US20040231006A1 (en) * | 2000-04-12 | 2004-11-18 | Silver Daniel P. | Self-extinguishing recombinases, nucleic acids encoding them and methods of using the same |
ATE427994T1 (de) | 2000-04-12 | 2009-04-15 | Dana Farber Cancer Inst Inc | Selbstlíschende rekombinasen, dafur kodierende nukleinsauren und verfahren zu deren verwendung |
FR2810046B1 (fr) * | 2000-06-07 | 2004-09-10 | Neurotech | Procede d'immortalisation conditionnelle de cellules et les constructions proteiques pour sa mise en oeuvre |
JP4185264B2 (ja) * | 2001-07-02 | 2008-11-26 | 富士フイルム株式会社 | 偏光方向制御素子及び露光装置 |
JP2003033179A (ja) * | 2001-07-05 | 2003-02-04 | Asahi Kasei Corp | 可逆的遺伝子導入ベクター |
US6645763B2 (en) * | 2001-10-12 | 2003-11-11 | Naoya Kobayashi | Immortalized bone marrow mesenchymal stem cell |
GB0300208D0 (en) * | 2003-01-06 | 2003-02-05 | Oxford Biomedica Ltd | Insulin producing cells |
US7485457B2 (en) * | 2003-04-17 | 2009-02-03 | United States Of America Department Of Veterans Affairs | Isolated/cloned human NT2 cell lines expressing serotonin and GABA |
GB0316882D0 (en) | 2003-07-18 | 2003-08-20 | Consejo Superior Investigacion | Reversible immortalization of OEG from human olfactory bulbs as a tool to promote spinal cord regeneration |
CA2584738A1 (en) * | 2004-10-20 | 2006-04-27 | Vitro Diagnostics, Inc. | Generation and differentiation of adult stem cell lines |
US20070093439A1 (en) * | 2005-10-25 | 2007-04-26 | Idera Pharmaceuticals, Inc. | Short immunomodulatory oligonucleotides |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1293460C (en) * | 1985-10-07 | 1991-12-24 | Brian Lee Sauer | Site-specific recombination of dna in yeast |
US5399346A (en) * | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
WO1992015694A1 (en) * | 1991-03-08 | 1992-09-17 | The Salk Institute For Biological Studies | Flp-mediated gene modification in mammalian cells, and compositions and cells useful therefor |
WO1993001283A1 (en) * | 1991-07-08 | 1993-01-21 | The United States Of America As Represented By The Secretary Of Agriculture | Selection-gene-free transgenic plants |
WO1993022443A1 (en) * | 1992-04-24 | 1993-11-11 | Sri International | In vivo homologous sequence targeting in eukaryotic cells |
CA2140884A1 (en) * | 1992-07-27 | 1994-02-03 | David J. Anderson | Mammalian multipotent neural stem cells |
US5387237A (en) * | 1992-07-30 | 1995-02-07 | The University Of Toledo | Bioartificial pancreas |
-
1995
- 1995-06-07 US US08/481,127 patent/US5629159A/en not_active Expired - Lifetime
-
1996
- 1996-06-06 AT AT96918405T patent/ATE255632T1/de not_active IP Right Cessation
- 1996-06-06 AU AU61077/96A patent/AU700690B2/en not_active Ceased
- 1996-06-06 ES ES96918405T patent/ES2211959T3/es not_active Expired - Lifetime
- 1996-06-06 WO PCT/US1996/009781 patent/WO1996040877A1/en active Search and Examination
- 1996-06-06 EP EP96918405A patent/EP0832196B1/en not_active Expired - Lifetime
- 1996-06-06 DE DE69630955T patent/DE69630955T2/de not_active Expired - Fee Related
- 1996-06-06 JP JP50200397A patent/JP3875267B2/ja not_active Expired - Fee Related
- 1996-06-06 CA CA002222425A patent/CA2222425C/en not_active Expired - Fee Related
-
1997
- 1997-12-02 NO NO19975557A patent/NO323174B1/no unknown
Also Published As
Publication number | Publication date |
---|---|
EP0832196B1 (en) | 2003-12-03 |
US5629159A (en) | 1997-05-13 |
AU6107796A (en) | 1996-12-30 |
ATE255632T1 (de) | 2003-12-15 |
WO1996040877A1 (en) | 1996-12-19 |
CA2222425C (en) | 2007-08-21 |
ES2211959T3 (es) | 2004-07-16 |
AU700690B2 (en) | 1999-01-14 |
DE69630955D1 (de) | 2004-01-15 |
DE69630955T2 (de) | 2004-10-21 |
CA2222425A1 (en) | 1996-12-19 |
NO975557L (no) | 1998-02-05 |
EP0832196A1 (en) | 1998-04-01 |
JPH11507230A (ja) | 1999-06-29 |
NO975557D0 (no) | 1997-12-02 |
JP3875267B2 (ja) | 2007-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO323174B1 (no) | Immortalisert patterdyrcellelinje og fremgangsmate for immortalisering og dissimortalisering av celler | |
US11485959B2 (en) | Hyperactive piggybac transposases | |
JP4024830B2 (ja) | Hhv−7由来の組換ウイルスベクター、その製造方法、それを用いた宿主細胞の形質転換方法、それにより形質転換された宿主細胞およびそれを用いた遺伝子治療方法 | |
US20030049236A1 (en) | Immortalized stem cells | |
JP2006517101A (ja) | 治療用産物を送達するための、増殖性の幹細胞および前駆細胞における候補分子の持続的発現 | |
WO2003010305A1 (en) | Immortilized stem cells | |
KR20080016888A (ko) | 지방세포 또는 전구 지방세포로의 유전자 도입 방법 | |
US6936465B1 (en) | Plasmid vector comprising a retroviral integrase gene and an integrase recognition region | |
Ishii et al. | Somatic transgenesis in the avian model system | |
US20020006660A1 (en) | Genetically-modified neural progenitors and uses thereof | |
MXPA97009783A (es) | Inmortalizacion y desinmortalizacion de celulas | |
Petitte | The avian germline and strategies for the production of transgenic chickens | |
CN117683747A (zh) | 基因激活系统、方法及其应用 | |
WO2001019853A2 (en) | Cell transfection | |
WO2006027606A2 (en) | Screening method | |
KR20090034524A (ko) | 사람 혈액의 과립구집락자극인자(hG-CSF) 유전자를내장하는 레트로바이러스 발현벡터 및 이에 의해형질전환된 가금 |